Research Analysts Set Expectations for CAPR Q2 Earnings

Capricor Therapeutics Inc (NASDAQ:CAPR) – Investment analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for shares of Capricor Therapeutics in a research note issued on Thursday, March 20th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will post earnings per share of ($0.36) for the quarter. HC Wainwright has a “Buy” rating and a $77.00 price objective on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.21) per share.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.15. The company had revenue of $11.13 million for the quarter, compared to analysts’ expectations of $9.87 million. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%.

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $30.00 target price on shares of Capricor Therapeutics in a research note on Thursday. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $34.50.

Capricor Therapeutics Stock Performance

NASDAQ CAPR opened at $14.36 on Friday. The company’s 50-day simple moving average is $14.06 and its two-hundred day simple moving average is $14.50. The company has a market capitalization of $652.95 million, a price-to-earnings ratio of -13.55 and a beta of 4.10. Capricor Therapeutics has a one year low of $3.52 and a one year high of $23.40.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Summit Investment Advisors Inc. boosted its stake in shares of Capricor Therapeutics by 54.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 1,345 shares during the period. Russell Investments Group Ltd. lifted its holdings in Capricor Therapeutics by 172.8% during the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock worth $64,000 after buying an additional 2,947 shares in the last quarter. Virtus ETF Advisers LLC purchased a new position in Capricor Therapeutics in the 4th quarter valued at approximately $68,000. AlphaQuest LLC acquired a new position in shares of Capricor Therapeutics in the fourth quarter worth $78,000. Finally, New York State Common Retirement Fund increased its position in shares of Capricor Therapeutics by 625.0% during the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 5,000 shares during the period. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.